359 related articles for article (PubMed ID: 21461989)
1. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.
Dressel R
Semin Immunopathol; 2011 Nov; 33(6):573-91. PubMed ID: 21461989
[TBL] [Abstract][Full Text] [Related]
2. Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules.
Dressel R; Guan K; Nolte J; Elsner L; Monecke S; Nayernia K; Hasenfuss G; Engel W
Biol Direct; 2009 Aug; 4():31. PubMed ID: 19715575
[TBL] [Abstract][Full Text] [Related]
3. Highly sensitive biosafety model for stem-cell-derived grafts.
Lawrenz B; Schiller H; Willbold E; Ruediger M; Muhs A; Esser S
Cytotherapy; 2004; 6(3):212-22. PubMed ID: 15203978
[TBL] [Abstract][Full Text] [Related]
4. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
5. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response.
Dressel R; Schindehütte J; Kuhlmann T; Elsner L; Novota P; Baier PC; Schillert A; Bickeböller H; Herrmann T; Trenkwalder C; Paulus W; Mansouri A
PLoS One; 2008 Jul; 3(7):e2622. PubMed ID: 18612432
[TBL] [Abstract][Full Text] [Related]
6. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression.
Magliocca JF; Held IK; Odorico JS
Stem Cells Dev; 2006 Oct; 15(5):707-17. PubMed ID: 17105406
[TBL] [Abstract][Full Text] [Related]
7. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium.
Swijnenburg RJ; Tanaka M; Vogel H; Baker J; Kofidis T; Gunawan F; Lebl DR; Caffarelli AD; de Bruin JL; Fedoseyeva EV; Robbins RC
Circulation; 2005 Aug; 112(9 Suppl):I166-72. PubMed ID: 16159810
[TBL] [Abstract][Full Text] [Related]
8. Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.
Tang C; Drukker M
Semin Immunopathol; 2011 Nov; 33(6):563-72. PubMed ID: 21479877
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.
Tang C; Weissman IL; Drukker M
Methods Mol Biol; 2013; 1029():17-31. PubMed ID: 23756939
[TBL] [Abstract][Full Text] [Related]
10. Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.
Itakura G; Kobayashi Y; Nishimura S; Iwai H; Takano M; Iwanami A; Toyama Y; Okano H; Nakamura M
PLoS One; 2015; 10(2):e0116413. PubMed ID: 25706286
[TBL] [Abstract][Full Text] [Related]
11. The safety of human pluripotent stem cells in clinical treatment.
Simonson OE; Domogatskaya A; Volchkov P; Rodin S
Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
[TBL] [Abstract][Full Text] [Related]
12. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells.
Dressel R; Nolte J; Elsner L; Novota P; Guan K; Streckfuss-Bömeke K; Hasenfuss G; Jaenisch R; Engel W
FASEB J; 2010 Jul; 24(7):2164-77. PubMed ID: 20145206
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of pluripotent stem cells and their derivatives.
de Almeida PE; Ransohoff JD; Nahid A; Wu JC
Circ Res; 2013 Feb; 112(3):549-61. PubMed ID: 23371903
[TBL] [Abstract][Full Text] [Related]
14. Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity.
Fairchild PJ; Horton C; Lahiri P; Shanmugarajah K; Davies TJ
Regen Med; 2016 Dec; 11(8):817-829. PubMed ID: 27905261
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells.
Benabdallah B; Désaulniers-Langevin C; Colas C; Li Y; Rousseau G; Guimond JV; Haddad E; Beauséjour C
Front Immunol; 2019; 10():2580. PubMed ID: 31787975
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of human embryonic stem cells: can we achieve tolerance?
Drukker M
Springer Semin Immunopathol; 2004 Nov; 26(1-2):201-13. PubMed ID: 15549307
[TBL] [Abstract][Full Text] [Related]
17. Complement-dependent control of teratoma formation by embryonic stem cells.
Koch CA; Jordan CE; Platt JL
J Immunol; 2006 Oct; 177(7):4803-9. PubMed ID: 16982921
[TBL] [Abstract][Full Text] [Related]
18. In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages.
Kadereit S; Trounson A
Semin Immunopathol; 2011 Nov; 33(6):551-62. PubMed ID: 21461990
[TBL] [Abstract][Full Text] [Related]
19. Heterelogous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives.
Zhao L; Teklemariam T; Hantash BM
Stem Cell Res; 2014 Sep; 13(2):342-54. PubMed ID: 25218797
[TBL] [Abstract][Full Text] [Related]
20. Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers.
Pizzato HA; Alonso-Guallart P; Woods J; Connelly JP; Fehniger TA; Atkinson JP; Pruett-Miller SM; Monsma FJ; Bhattacharya D
Stem Cell Reports; 2024 Feb; 19(2):299-313. PubMed ID: 38215755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
